KNIGHT THERAPEUTICS INC (GUD.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:GUD - CA4990531069 - Common Stock
6.05 CAD
0 (0%)
Taking everything into account, GUD scores 4 out of 10 in our fundamental rating. GUD was compared to 32 industry peers in the Pharmaceuticals industry. GUD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GUD is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year GUD has reported negative net income.
In the past year GUD had a positive cash flow from operations.
In multiple years GUD reported negative net income over the last 5 years.
Of the past 5 years GUD 4 years had a positive operating cash flow.
1.2 Ratios
GUD has a Return On Assets of -0.33%. This is in the better half of the industry: GUD outperforms 62.50% of its industry peers.
GUD's Return On Equity of -0.46% is fine compared to the rest of the industry. GUD outperforms 65.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.33% | ||
| ROE | -0.46% | ||
| ROIC | N/A |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GUD's Profit Margin has declined in the last couple of years.
The Gross Margin of GUD (42.49%) is comparable to the rest of the industry.
GUD's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for GUD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
GUD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GUD has been reduced compared to 1 year ago.
Compared to 5 years ago, GUD has less shares outstanding
The debt/assets ratio for GUD has been reduced compared to a year ago.
2.2 Solvency
GUD has an Altman-Z score of 2.11. This is not the best score and indicates that GUD is in the grey zone with still only limited risk for bankruptcy at the moment.
GUD has a Altman-Z score of 2.11. This is amongst the best in the industry. GUD outperforms 84.38% of its industry peers.
GUD has a debt to FCF ratio of 37.42. This is a negative value and a sign of low solvency as GUD would need 37.42 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 37.42, GUD is in line with its industry, outperforming 56.25% of the companies in the same industry.
GUD has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
GUD has a Debt to Equity ratio of 0.11. This is in the better half of the industry: GUD outperforms 65.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 37.42 | ||
| Altman-Z | 2.11 |
ROIC/WACCN/A
WACC8.56%
2.3 Liquidity
GUD has a Current Ratio of 2.62. This indicates that GUD is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 2.62, GUD is doing good in the industry, outperforming 68.75% of the companies in the same industry.
GUD has a Quick Ratio of 1.68. This is a normal value and indicates that GUD is financially healthy and should not expect problems in meeting its short term obligations.
GUD has a Quick ratio of 1.68. This is in the better half of the industry: GUD outperforms 78.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.68 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 93.10% over the past year.
GUD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.46% yearly.
Looking at the last year, GUD shows a quite strong growth in Revenue. The Revenue has grown by 18.70% in the last year.
The Revenue has been growing by 50.87% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)93.1%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-4850%
Revenue 1Y (TTM)18.7%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%31.74%
3.2 Future
Based on estimates for the next years, GUD will show a very strong growth in Earnings Per Share. The EPS will grow by 55.65% on average per year.
GUD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.50% yearly.
EPS Next Y-330.28%
EPS Next 2Y10.09%
EPS Next 3Y50.87%
EPS Next 5Y55.65%
Revenue Next Year14.81%
Revenue Next 2Y12.31%
Revenue Next 3Y8.59%
Revenue Next 5Y10.5%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
GUD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 99.83, the valuation of GUD can be described as expensive.
62.50% of the companies in the same industry are more expensive than GUD, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.10, GUD is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 99.83 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as GUD.
The rest of the industry has a similar Price/Free Cash Flow ratio as GUD.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 211.59 | ||
| EV/EBITDA | 12.57 |
4.3 Compensation for Growth
GUD's earnings are expected to grow with 50.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.09%
EPS Next 3Y50.87%
5. Dividend
5.1 Amount
GUD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:GUD (12/5/2025, 7:00:00 PM)
6.05
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners14.23%
Inst Owner ChangeN/A
Ins Owners1.86%
Ins Owner ChangeN/A
Market Cap600.70M
Revenue(TTM)413.85M
Net Income(TTM)-3.49M
Analysts78.18
Price Target8.03 (32.73%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-753.57%
Min EPS beat(2)-815.07%
Max EPS beat(2)-692.08%
EPS beat(4)2
Avg EPS beat(4)-169.96%
Min EPS beat(4)-815.07%
Max EPS beat(4)461.4%
EPS beat(8)2
Avg EPS beat(8)-354.72%
EPS beat(12)5
Avg EPS beat(12)-190.89%
EPS beat(16)7
Avg EPS beat(16)-395.3%
Revenue beat(2)2
Avg Revenue beat(2)11.78%
Min Revenue beat(2)11.06%
Max Revenue beat(2)12.49%
Revenue beat(4)4
Avg Revenue beat(4)8.38%
Min Revenue beat(4)0.88%
Max Revenue beat(4)12.49%
Revenue beat(8)7
Avg Revenue beat(8)5.34%
Revenue beat(12)11
Avg Revenue beat(12)8.81%
Revenue beat(16)14
Avg Revenue beat(16)8.72%
PT rev (1m)0.92%
PT rev (3m)0.92%
EPS NQ rev (1m)-100%
EPS NQ rev (3m)-100%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)4.51%
Revenue NQ rev (3m)4.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 99.83 | ||
| P/S | 1.45 | ||
| P/FCF | 211.59 | ||
| P/OCF | 16.9 | ||
| P/B | 0.78 | ||
| P/tB | 2.02 | ||
| EV/EBITDA | 12.57 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0.06
Fwd EY1%
FCF(TTM)0.03
FCFY0.47%
OCF(TTM)0.36
OCFY5.92%
SpS4.17
BVpS7.72
TBVpS2.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.33% | ||
| ROE | -0.46% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.49% | ||
| FCFM | 0.69% |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
F-Score5
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 37.42 | ||
| Debt/EBITDA | 1.93 | ||
| Cap/Depr | 58.99% | ||
| Cap/Sales | 7.91% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 80.91% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.68 | ||
| Altman-Z | 2.11 |
F-Score5
WACC8.56%
ROIC/WACCN/A
Cap/Depr(3y)40.08%
Cap/Depr(5y)130.51%
Cap/Sales(3y)6.77%
Cap/Sales(5y)24.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.1%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-4850%
EPS Next Y-330.28%
EPS Next 2Y10.09%
EPS Next 3Y50.87%
EPS Next 5Y55.65%
Revenue 1Y (TTM)18.7%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%31.74%
Revenue Next Year14.81%
Revenue Next 2Y12.31%
Revenue Next 3Y8.59%
Revenue Next 5Y10.5%
EBIT growth 1Y-395.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year397.68%
EBIT Next 3Y80.27%
EBIT Next 5Y56.34%
FCF growth 1Y-63.88%
FCF growth 3YN/A
FCF growth 5Y23.85%
OCF growth 1Y56.3%
OCF growth 3Y-6.66%
OCF growth 5Y51.14%
KNIGHT THERAPEUTICS INC / GUD.CA FAQ
Can you provide the ChartMill fundamental rating for KNIGHT THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 4 / 10 to GUD.CA.
Can you provide the valuation status for KNIGHT THERAPEUTICS INC?
ChartMill assigns a valuation rating of 2 / 10 to KNIGHT THERAPEUTICS INC (GUD.CA). This can be considered as Overvalued.
What is the profitability of GUD stock?
KNIGHT THERAPEUTICS INC (GUD.CA) has a profitability rating of 2 / 10.
What is the financial health of KNIGHT THERAPEUTICS INC (GUD.CA) stock?
The financial health rating of KNIGHT THERAPEUTICS INC (GUD.CA) is 6 / 10.
Can you provide the expected EPS growth for GUD stock?
The Earnings per Share (EPS) of KNIGHT THERAPEUTICS INC (GUD.CA) is expected to decline by -330.28% in the next year.